GNI Group, Gyre's controlling shareholder, reports 9M 2023 revenue ¥20.5B (+61%), net profit ¥2.2B (+106%)

GYRE THERAPEUTICS, INC.

9M 2023 revenue of ¥20,547.9M, up 61% from ¥12,761.0M in prior year.
Net profit attributable to parent ¥2,213.3M vs ¥1,076.1M, more than doubled.
Operating cash flow ¥4,443.0M, turning from negative ¥162.9M in prior year.
Total assets ¥48,468.0M, up 33% from ¥36,456.9M at prior year-end.
Basic EPS ¥46.61 (9M) vs ¥22.67; diluted EPS ¥46.13 vs ¥22.46.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.